welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Non-Invasive Prediction of Colorectal Neoplasia
study id #: NCT01815463
condition: Colonic Polyps , Polyposis Coli , Colorectal Cancer
status: terminated
purpose:Hypothesis:The Adnab-9 antigen is a predictive biomarker in individuals at risk of developing colorectal neoplasia.
Study aim is to evaluate the potential of the Adnab-9 monoclonal antibody (MAb) as a marker of cancer risk in a population at increased risk for colorectal cancer (CRC). This marker would be compared to other current and emerging diagnostic methods. 2,800 Veterans would be recruited into the study. In phase 1, candidates would be defined as having increased CRC risk by a short questionnaire. Stool samples would be obtained and a semi-quantitative Adnab-9 antigen assay (ELISA) would be determined. Patients with differing high and low estimations of fecal Adnab-9 would undergo colonoscopy at which time other samples of effluent and colonic mucosa would be taken, and a detailed lifestyle and nutritional questionnaire would be completed. The characteristics of the Adnab-9 fecal test as a diagnostic test would be critically determined using the outcome of the colonoscopic and other test results. The patients will be contacted through the mail and by word of mouth. Informed consent will be obtained before the samples are obtained. The participants are clinically defined as high-risk and therefore screening colonoscopy would be likely performed in any event. A number of assays for Adnab-9 are feasible including slot-blot, Western blot, and ELISA. Other stool studies include conventional fecal occult blood tests (FOBT or FIT) that will be performed in tandem. The investigators therefore began this method of collection and obtained consent from over 2000 patients with a similar overall compliance rate with FOBT screening procedures to that reported previously of approximately 50%. Currently the study is no longer enrolling patients at the Detroit VA and is now finalizing data entry. Another 450 patients to be recruited at the Philadelphia VAMC.
expertly curated content related to this topic
-
Combination Treatment with Curcumin and Quercetin of Adenomas in Familial Adenomatous PolyposisBACKGROUND & AIMS : Familialadenomat...
-
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersA pharmacokinetic study in healthy volun...
-
Discussing Pediatric Familial Polyposis and Colorectal Cancerhttps://youtu.be/km3FYvoOV94...
-
Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CWThere is a need for better visualization...
-
Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposi...Abstract To identify gene expression bi...
-
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatou...Exisulind (sulindac sulfone; FGN-1), a m...
-
Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical TrialsThis chapter briefly summarizes the curr...